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Short Communication
Antitumour activity of platinum analogues against human
yolk sac tumours heterotransplanted in nude mice
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Osaka University, Suita-City, Osaka, Japan
Cis-Diamminedichloroplatinum II (CDDP) has been
recognized as one of the most active drugs against
malignant tumours including ovarian cancer. How-
ever, CDDP is a toxic drug causing emesis, renal
failure, hearing loss, neuropathy and anaemia. In
view of these toxicities many investigators have
attempted to develop new platinum analogues
which retain anti-tumour activity with less toxicity.
Among a large number of platinum analogues,
cis-diammine-l, 1-cyclobutane dicarboxylate platinum
II (CBDCA) and cis-dichloro-trans-dihydroxy-bis-
isopropylamine platinum IV (CHIP) have been
selected as promising compounds and projected
for clinical trials (Calvert et al., 1982; Creaven
et al., 1983). There have been several reports on
the clinical efficacy of CBDCA and CHIP as
anti-cancer drugs. However, few studies have
reported the simultaneous testing of the antitumour
activities of CBDCA, CHIP and CDDP against
heterotransplanted human tumours (Wolpert-
DeFilippes, 1980; Harrap et al., 1980; Boven et al.,
1985). These reports revealed that ovarian
undifferentiated carcinoma (Boven et al., 1985)
and epidermoid carcinoma (Harrap et al., 1980)
responded to CBDCA, whereas colon, lung and
mammary xenografted tumours were generally
refractory to new platinum analogues including
CBDCA and CHIP (Wolpert-DeFilippes, 1980).
In 1977, we successfully transplanted tissues from
human yolk sac tumours of the ovary into nude
mice, and three of these have been maintained by
serial transplantation in nude mice in our
laboratory (Sawada et al., 1981; 1982). We
previously reported that the tumours responded
well to CDDP combination chemotherapy (Sawada
et al., 1983). In this preliminary study, we have
examined the therapeutic responses of ovarian yolk
sac tumours to CBDCA, CHIP and CDDP.
The human yolk sac tumours (YST-1, YST-2 and
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YST-3) used in this study were established by
inoculation of fresh tumour tissues from three
different patients into BALB/C female nude mice in
our laboratory, as previously described (Sawada et
al., 1981; 1982). The tumours were cut into small
pieces (2-4mm3) in ice-cold Eagle's minimum
essential medium and transplanted s.c. into nude
mice by trocar. At the time of these experiments the
number of previous tumour tissue passages ranged
from 20 to 30. The tumour take rate for all the
tumour lines was 90-100%.
CBDCA was supplied by the Drug Synthesis and
Chemistry Branch, National Cancer Institute
(NCI), USA. CHIP and CDDP were supplied by
Bristol-Myers Company. CDDP was dissolved in
0.2ml 0.9% NaCl solution, and CBDCA and CHIP
were dissolved in 0.2ml distilled water. Fifty
mgkg- of CBDCA, 25mgkg-1 of CHIP and
6mgkg-1 of CDDP were administered i.p. into
tumour-bearing nude mice three times with
intervals of 4 days. Control mice were injected i.p.
with 0.2ml 0.9% NaCl. The dosages used in this
experiment were based on the results in the NCI
File Comparative studies of cisplatin and platinum
containing analogues reported by the Platinum
Analogue Working Group in 1980.
When the tumours became palpable and were
growing progressively, experimental mice were
randomized into test groups of 5-10 mice (one
tumour each). The size of the implant was
measured with slide calipers twice a week, and the
volume (V), in mm3, was calculated by the formula
described by Houchens et al. (1978): V=
Wx Lx 1/2, where W and L are the width and
length in mm. For comparison with different
groups, the relative tumour volume (RV) for each
group was calculated from the formula RV= Vi/Vo,
where Vi=the mean tumour volume at any given
time and Vo=the mean initial tumour volume
when treatment was begun. TIC (ratio of RV for
treated mice to RV for control mice, multiplied by
100) was calculated at each measurement.
Treatment of the YST-1 tumours was initiated 25
days post transplantation. As shown in Figure 1,
CDDP significantly decreased the tumour volume
(P<0.01) and CBDCA slightly suppressed tumour
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Figure 1 Response to chemotherapy (shown as relative tumour volume) of YST-1, YST-2 and YST-3 human
yolk sac tumours in nude mice. (0) controls; (0) CDDP treated tumours; (A) CBDCA treated tumours; (U)
CHIP treated tumours. The numbers of animals (=tumours) used for each group are indicated in Table I.
Arrows indicate injection of each drug.
Table I Summary of the effect of CDDP, CBDCA and CHIP on human
yolk sac tumours heterotransplanted in nude mice.
Tumour No. of
line Treatment mice TIC volume (P) (Day)
YST-1 NaCl (controls) 7
CDDP 8 7.4 (<0.01) (25)
CBDCA 9 35.6 (<0.05) (21)
CHIP 7 58.0 (<0.4) (30)
YST-2 NaCl (controls) 9
CDDP 7 2.7 (<0.05) (27)
CBDCA 10 7.1 (<0.01) (15)
CHIP 9 5.0 (<0.01) (21)
YST-3 NaCl (controls) 7
CDDP 6 10.7 (<0.05) (27)
CBDCA 5 13.8 (<0.05) (21)
CHIP 9 22.2 (<0.05) (15)
aAnalysis was performed for control group vs. treated groups, with the
use of Student's t-test.
growth (P<0.05). CHIP did not significantly affect
the growth of YST-1 (Table I).
Treatment of the YST-2 tumour was initiated 22
days post transplantation. As shown in Figure 1,
CDDP, CBDCA and CHIP all significantly
suppressed the growth of YST-2. The tumour
disappeared in one of 7 mice treated with CDDP,
in 2 of 10 mice treated with CBDCA and in one of
9 mice treated with CHIP. No statistical difference
in the antitumour activity of these drugs was
observed between CDDP-, CBDCA-, CHIP-treated
groups (Table I).
Treatment of the YST-3 tumour was initiated 28
days post transplantation. As shown in Figure 1,
CDDP, CBDCA and CHIP all suppressed tumour
growth. Although the YST-3 tumour seemed to
respond more quickly to CDDP and CBDCA, no
statistical difference in the T/C values was observed
between the CDDP-, CBDCA-, and CHIP-treated
groups (Table I).
While tumours YST-2 and YST-3 exhibit broadly
comparable sensitivity to CDDP and the two
analogues, YST-1 is substantially more sensitive to
CDDP than to CBDCA or CHIP. This result
reflects the clinical response of that small
proportion (25%) of ovarian cancer patients who
had received CDDP treatment and responded
subsequently to CBDCA (Evans et al., 1983).
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Human nude mice models may be more clinically
predictive of platinum response than conventional
rodent transplant models.
Of course it is impossible to select a drug as the
most effective against yolk sac tumours on the basis
of efficacy at a single dose. The dosages used in
the present study were less than the lethal dose for
nude mice and about one-third of the LD50 for
conventional mice, reported by other investigators
(Wilkinson et al., 1978; Bradner et al., 1980;
Schurig et al., 1980; Shepherd et al., 1980; Lelieveld
et al., 1984). The doses used here are in the right
range because they appear equally toxic in terms of
mean body weight as a percentage ofstarting weight.
The largest decrease (15%) in mean body weight
was observed on days 8-12. But the decrease was
not statistically different between the CDDP-,
CBDCA-, and CHIP-treated groups. No mice died
during this experiment.
The point of the new platinum analogues is
amelioration of the particular problem of renal
toxicity. Since our primary interest was to examine
the anti-tumour activity of CDDP, CBDCA and
CHIP, we did not evaluate renal damage in the
mouse. Detailed discription of the specific toxicity
of new platinum analogues has been given by other
investigators (Harrap et al., 1980; Boven et al.,
1985).
More data are required for a detailed comparison
of the antitumour effects of platinum analogues
against ovarian cancer. Further studies are in
progress using newly established epithelial ovarian
tumours (Sawada et al., 1985), because germ cell
tumours of the ovary have a different spectrum of
chemotherapeutic sensitivities from epithelial
ovarian cancer (Hakes, 1984).
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